Bioinformatics -- the marriage of biology and information technology -- is changing the way scientists study disease and develop medicines, replacing hours of tedious laboratory work with a few mouse clicks.
But bioinformatics companies, which captured Wall Street's imagination in the late 1990s, are losing their luster with investors. For instance, shares of InforMax Inc., a Bethesda software maker, are trading near their all-time low.
Yet Stephen E. Lincoln, InforMax's chief scientific officer, is as bullish as ever on the future of the industry.
Full story can be found in the Washington Post, March 14, 2002.
Message posted by: Anthony W.I. Lo